Physician profile
Steven Graham
NPI 1295713584
$11,884.72
in general payments reported to CMS, 2019-2025
41 companies · $3,085 in 2025
The $3,085 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2021: $1,040 · 2022: $1,797 · 2023: $2,371 · 2024: $2,780 · 2025: $3,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,086 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,086.26 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,370.53 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Novartis Pharmaceuticals Corporation | $1,117.32 | 2019-2025 | |
| Abbvie INC. | $905.07 | 2019-2025 | |
| Pfizer INC. | $863.46 | 2019-2025 | |
| Ucb, INC. | $689.79 | 2023-2025 | Rystiggo, Zilbrysq |
| Lundbeck LLC | $657.12 | 2021-2025 | Vyepti |
| Sk Life Science, INC. | $577.42 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $571.06 | 2019-2025 | Ultomiris |
| Emd Serono, INC. | $535.44 | 2019-2025 | Mavenclad |
| Amgen INC. | $462.27 | 2019-2025 | Uplizna |
| Eisai INC. | $448.34 | 2022-2025 | |
| Merz Pharmaceuticals, LLC | $422.10 | 2022-2025 | Xeomin, Ampyra, Inbrija |
| Argenx US, INC. | $395.36 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $346.17 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Tg Therapeutics, INC. | $337.68 | 2023-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.